Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 20 Jan 2018 Results of the secondary analysis assessing the safety and efficacy of the 4 dosing regimens, presented at the 2018 Gastrointestinal Cancers Symposium
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top